Using the concordance of in vitro and in vivo data to evaluate extrapolation assumptions
Open Access
- 28 May 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (5), e0217564
- https://doi.org/10.1371/journal.pone.0217564
Abstract
Linking in vitro bioactivity and in vivo toxicity on a dose basis enables the use of high-throughput in vitro assays as an alternative to traditional animal studies. In this study, we evaluated assumptions in the use of a high-throughput, physiologically based toxicokinetic (PBTK) model to relate in vitro bioactivity and rat in vivo toxicity data. The fraction unbound in plasma (fup) and intrinsic hepatic clearance (Clint) were measured for rats (for 67 and 77 chemicals, respectively), combined with fup and Clint literature data for 97 chemicals, and incorporated in the PBTK model. Of these chemicals, 84 had corresponding in vitro ToxCast bioactivity data and in vivo toxicity data. For each possible comparison of in vitro and in vivo endpoint, the concordance between the in vivo and in vitro data was evaluated by a regression analysis. For a base set of assumptions, the PBTK results were more frequently better associated than either the results from a “random” model parameterization or direct comparison of the “untransformed” values of AC50 and dose (performed best in 51%, 28%, and 21% of cases, respectively). We also investigated several assumptions in the application of PBTK for IVIVE, including clearance and internal dose selection. One of the better assumptions sets–restrictive clearance and comparing free in vivo venous plasma concentration with free in vitro concentration–outperformed the random and untransformed results in 71% of the in vitro-in vivo endpoint comparisons. These results demonstrate that applying PBTK improves our ability to observe the association between in vitro bioactivity and in vivo toxicity data in general. This suggests that potency values from in vitro screening should be transformed using in vitro-in vivo extrapolation (IVIVE) to build potentially better machine learning and other statistical models for predicting in vivo toxicity in humans.This publication has 51 references indexed in Scilit:
- Dose metric considerations in in vitro assays to improve quantitative in vitro–in vivo dose extrapolationsToxicology, 2015
- Incorporating New Technologies Into Toxicity Testing and Risk Assessment: Moving From 21st Century Vision to a Data-Driven FrameworkToxicological Sciences, 2013
- Improving the Human Hazard Characterization of Chemicals: A Tox21 UpdateEnvironmental Health Perspectives, 2013
- Profiling the activity of environmental chemicals in prenatal developmental toxicity studies using the U.S. EPA's ToxRefDBReproductive Toxicology, 2009
- The Toxicity Data Landscape for Environmental ChemicalsEnvironmental Health Perspectives, 2009
- Profiling the Reproductive Toxicity of Chemicals from Multigeneration Studies in the Toxicity Reference DatabaseToxicological Sciences, 2009
- Profiling Chemicals Based on Chronic Toxicity Results from the U.S. EPA ToxRef DatabaseEnvironmental Health Perspectives, 2009
- National Toxicology Program Studies: Principles of Dose Selection and Applications to Mechanistic Based Risk AssessmentFundamental and Applied Toxicology, 1996
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973
- Brownian motion in a field of force and the diffusion model of chemical reactionsPhysica, 1940